Wilson Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Wilson Disease pipeline constitutes 5+ key companies continuously working towards developing 5+ Wilson Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Wilson Disease Overview
Wilson's Disease is characterized by excess copper stored in various body tissues, particularly the liver, brain, and corneas of the eyes. Wilson's disease (WD) is a rare genetic disorder beginning with liver dysfunction where damage begins by 6 years of age, but it is usually present clinically in the teenage years or early 20s. Wilson disease is inherited as an autosomal recessive trait. A mutation in the ATP7B gene, which codes for copper transportation, causes WD.

"Wilson Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Wilson Disease Market. https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

The Wilson Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Wilson Disease Pipeline Report:
• Companies across the globe are diligently working toward developing novel Wilson Disease treatment therapies with a considerable amount of success over the years. Wilson Disease Key players such as - Generation Bio, Deep genomics, Depymed Inc., Vivet therapeutics, Alexion, AstraZeneca, Univar BV, and others, are developing therapies for the Wilson Disease treatment
• Wilson Disease Emerging therapies such as - Research programme: gene therapies, DG 12P1, DPM-1001, VTX-801, ALXN1840, trientine dihydrochloride, ALXN1840, UX701, Bis-Choline Tetrathiomolybdate, and others are expected to have a significant impact on the Wilson Disease market in the coming years.
• In October 2021, Alexion Pharmaceuticals initiated a multicenter, randomized, controlled, open-label, Rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson Disease
• In December 2020, AstraZeneca and Alexion Pharmaceuticals entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders received $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share

Route of Administration
Wilson Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Wilson Disease Pipeline Therapeutics Assessment
• Wilson Disease Assessment by Product Type
• Wilson Disease By Stage and Product Type
• Wilson Disease Assessment by Route of Administration
• Wilson Disease By Stage and Route of Administration
• Wilson Disease Assessment by Molecule Type
• Wilson Disease by Stage and Molecule Type

DelveInsight's Wilson Disease Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Wilson Disease Therapeutics Market include:
Key companies developing therapies for Wilson Disease are - Alexion Pharmaceuticals, Vivet Therapeutics, Ultragenyx Pharmaceutical, Deep Genomics, Generation Bio, DepYmed, IncNobelpharma, Orphalan, and others.

Emerging Wilson Disease Drugs Under Different Phases of Clinical Development Include:
• Research programme: gene therapies: Generation Bio
• DG 12P1: Deep genomics
• DPM-1001: Depymed Inc.
• VTX-801: Vivet therapeutics
• ALXN1840: Alexion/AstraZeneca
• trientine dihydrochloride: Univar BV
• ALXN1840: Alexion
• UX701: Ultragenyx Pharmaceutical Inc
• Bis-Choline Tetrathiomolybdate: Alexion

Get a Free Sample PDF Report to know more about Wilson Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Wilson Disease Pipeline Analysis:
The Wilson Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Wilson Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wilson Disease Treatment.
• Wilson Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Wilson Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wilson Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Wilson Disease product details are provided in the report. Download the Wilson Disease pipeline report to learn more about the emerging Wilson Disease therapies at:
https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Wilson Disease Pipeline Market Drivers
• Increasing Wilson Disease prevalence
• Rising demand for rapid diagnosis and better treatment
• Growing health awareness

Wilson Disease Pipeline Market Barriers
• High cost of Wilson Disease drugs
• Lack of reimbursement policies
Scope of Wilson Disease Pipeline Drug Insight
• Coverage: Global
• Key Wilson Disease Companies: Generation Bio, Deep genomics, Depymed Inc., Vivet therapeutics, Alexion, AstraZeneca, Univar BV, and others
• Key Wilson Disease Therapies: Research programme: gene therapies, DG 12P1, DPM-1001, VTX-801, ALXN1840, trientine dihydrochloride, ALXN1840, UX701, Bis-Choline Tetrathiomolybdate, and others
• Wilson Disease Therapeutic Assessment: Wilson Disease current marketed and Wilson Disease emerging therapies
• Wilson Disease Market Dynamics: Wilson Disease market drivers and Wilson Disease market barriers

Request for Sample PDF Report for Wilson Disease Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Wilson Disease Report Introduction
2 Wilson Disease Executive Summary
3 Wilson Disease Overview
4 Wilson Disease- Analytical Perspective In-depth Commercial Assessment
5 Wilson Disease Pipeline Therapeutics
6 Wilson Disease Late Stage Products (Phase II/III)
7 Wilson Disease Mid Stage Products (Phase II)
8 Wilson Disease Early Stage Products (Phase I)
9 Wilson Disease Preclinical Stage Products
10 Wilson Disease Therapeutics Assessment
11 Wilson Disease Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Wilson Disease Key Companies
14 Wilson Disease Key Products
15 Wilson Disease Unmet Needs
16 Wilson Disease Market Drivers and Barriers
17 Wilson Disease Future Perspectives and Conclusion
18 Wilson Disease Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Wilson Disease drugs and therapies- https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Wilson Disease Market https://www.delveinsight.com/report-store/wilson-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Wilson Disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Wilson Disease Epidemiology https://www.delveinsight.com/report-store/wilson-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Wilson Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.